Would Outcomes-Based Contracting be Beneficial for Orphan Drugs?
Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, talks about the potential merits of outcomes-based contracting for drugs that treat rare diseases.
Outcomes-based contracting can be very beneficial for specialty pharmacies, and we certainly have a role to play. We are at the center of the patients care once they leave the physician’s office, particularly with the new oral and self-administered medications.
That being said, there’s only certain factors that as a pharmacy we can control related to those outcomes. So, I think where the value comes into outcomes-based contracting is really helping us as pharmacies show what we can control and how we can impact patient outcomes.